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Abstract
Introduction: Malignant Melanoma is becoming increasingly common. Recurrence is common in,
with late recurrence up to 10 years being recognised. We present a case of recurrent metastatic
melanoma 24 years after initial presentation, which is the longest interval reported to date.
Case presentation: EF presented with iron-deficiency anaemia, lethargy, and weight loss. He had
an enucleation of his left eye 24 years previously for a uveal melanoma. Endoscopy and biopsy
confirmed recurrent duodenal and gastric metastasis. A staging CT demonstrated wide spread
thoracic, liver, adrenal and bone metastasis. He was treated with palliative chemotherapy, and died
3 months later.
Conclusion: Late presentation of metastatic melanoma is common, and should be remembered
in patients with a distant history of melanoma. Even, as in our case, if the history is more than two
decades previously. Treatment options are poor; earlier recognition may lead to improved survival.
Introduction
Malignant melanoma is a neoplasm of the melanocyte. Its
annual incidence has increased dramatically in recent
years. It may develop in pre-existing lesions or can occur
de novo. Similarly, it can present in sun-exposed areas
(acute, intense sunburns are a definite risk factor) or in
unexposed areas (e.g. sole of foot, eye, etc.). It accounts
for 5% of all skin cancers, but causes 3 times more deaths
than other skin cancers.
Early diagnosis is crucial, as metastatic or advanced dis-
ease is associated with poorer prognosis. The commonest
site of presentation for men tends to be the trunk, and for
women is the lower limb [1].
Surgery is the treatment of choice for localised cutaneous
melanoma. Features that effect prognosis adversely are
tumour thickness in millimetres (i.e. Breslow's depth),
depth related to skin structures (i.e. Clark level), ulcera-
tion and presence of invasion. Adjunctive therapy, specif-
ically Interferon or Dacarbazine, may be of benefit in
patients with more advanced disease.
Recurrence of melanoma is common, even many years
after the initial diagnosis. We present the case of a man
presenting 24 years after his initial diagnosis, who under-
went "curative" treatment at the time.
Case presentation
EF is a 72 year old man who presented to our emergency
department in February 2009. He described a 4 month
history of fatigue and weight loss, with a 4 kg weight loss
in the preceding 8 weeks. He had noticed a change in
bowel habit, becoming constipated, over the last 3 weeks.
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Along with this history; he also complained of a dry, non-
productive cough in the preceding two months.
He had a long-standing history of Hypertension and
Hypercholesterolaemia; for which he was prescribed ator-
vastatin, perindopril and bendrofluazide.
He gave a history of a vision loss in his left eye due to a
"tumour", which required an enucleation of his left eye 24
years previously.
His routine laboratory investigations revealed a
hypochromic, microcytic anaemia (Haemoglobin 9.0 g/
dL (range 13-17 g/dL), Mean Cell Volume 74fl (range 80-
100fl), Mean Cell Haemoglobin 23.8 pg (range 27-32
pg)). His Erythrocyte Sedimentation Rate was elevated at
68 mm/hr (range 0-30 mm/hr). His renal and liver profile
was normal, although his albumin was noted to be low at
30 g/L (range 35-50 g/L). His Chest X-ray on admission
suggested hilar lymphadenopathy. His Faecal Occult
Blood Test was positive.
He proceeded to investigation of his iron-deficiency anae-
mia by gastroscopy and colonoscopy. His colonoscopy
was normal. His gastroscopy, however, revealed several
abnormalities. He was found to have a large, irregular fun-
gating ulcer in the fundus of his stomach (see Figure 1).
This measured 6-7 cms in maximal diameter. The appear-
ances of which were concerning for malignancy. A second
smaller ulcer was noted inferior to this. Three further
irregular ulcers were noted in the second part of his duo-
denum (see Figure 2). Their appearances were again wor-
risome for malignancy. These ulcers, in contrast to the
gastric ulcers however, were noted to have a quite marked
central pigmentation. He had multiple biopsies from
stomach and duodenum taken.
Histopathological examination revealed extensive
mucosal and sub-mucosal infiltration of gastric and duo-
denal tissue by a malignant tumour with a solid growth
pattern and pigment. Immunohistochemistry stains were
positive for S100 and negative for Keratin and CAM 5.2,
consistent with a diagnosis of metastatic melanoma.
He subsequently underwent a staging CT of Abdomen,
Thorax and Pelvis which confirmed the endoscopically
diagnosed mass in his stomach. He was noted also to have
abdominal and thoracic lymphadenopathy. Bilateral
adrenal metastases were seen, along with several ill-
defined lesions in his liver which were felt to represent fur-
ther metastasis. Multiple lung metastases and a probable
bone metastasis in a lumbar vertebra were also appreci-
ated.
He was informed of his diagnosis of metastatic
melanoma, and seen by the medical oncologists with a
view to palliative chemotherapy. He was commenced on
Temozolomide 150 mg/m2 (increasing to 200 mg/m2) for
five days and to be repeated every 4 weeks.
He was subsequently discharged and continued his chem-
otherapy as an out-patient. He tolerated his treatment rel-
atively well. However, despite this his disease progressed.
He subsequently died in May 2009.
Gastric Ulcer: Endoscopic picture of gastric metastatic  melanoma Figure 1
Gastric Ulcer: Endoscopic picture of gastric meta-
static melanoma.
Duodenal Ulcers: Endoscopic picture of duodenal metastatic  melanoma Figure 2
Duodenal Ulcers: Endoscopic picture of duodenal 
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Discussion
In retrospect, this man's prior ocular tumour was found to
be a primary uveal melanoma. At the time, he underwent
standard treatment which was enucleation of the affected
eye. This has largely been superceded recently by more
non-invasive treatments such as: radiotherapy, photoco-
agulation, thermotherapy, photo-dynamic therapy and
local resection. Efficacy rates are similar to enucleation[2],
but radiotherapy obviously has the benefit of being non-
invasive.
Late recurrence of melanoma is not uncommon, five and
ten-year recurrence rates are 25 and 34 percent respec-
tively[3]. Recurrence of melanoma up to 17 years after the
initial diagnosis has been reported [4]. The almost two
and a half decades reported here is unusual and has not
previously been recognised.
Uveal Melanoma has a five year survival rate of almost
60%, which has remained stable with newer, less invasive
treatments [2]. Metastases commonly present as liver
(approximately 20%) or lung lesions (about 30-35%).
Gastro-intestinal metastasis accounts for about 5% of
clinically apparent metastasis. Surveillance has been
shown to improve life-expectancy, but not mortality and
so is recommended post treatment with chest X-ray and
liver function tests with or without liver imaging [5].
Duration of screening is not well established.
The prognosis of metastatic melanoma is poor, and there
are no effective treatments. Median survival is reported as
2-12 months. The only licensed chemotherapeutic agent
for metastatic melanoma is Dacarbazine. Response rates
are modest at 6-15% (and almost all are described as par-
tial), with a response duration of only 7-8 months [6]. In
view of poor response rates, it is generally accepted that
using experimental or more convenient treatments is rea-
sonable. Temozolomide has been reported to have similar
response rates to Dacarbazine, but is administered orally
and so is a reasonable therapeutic option [6].
Conclusion
A diagnosis of recurrent metastatic melanoma should
always be considered in patients re-presenting in whom
there is a prior history of melanoma. Our case illustrates
that even after more than two decades since the initial
presentation, recurrence is possible. The surveillance of
patients after initial presentation remains problematic,
especially in the case of uveal melanoma. Specifics, sur-
rounding duration and type of surveillance remain unre-
solved. However, more problematic than those is the lack
of an effective treatment option. The evidence for improv-
ing life expectancy by surveillance is poor as a conse-
quence of a lack of a viable therapeutic option [5]. A
benefit is unlikely to be seen consistently unless a more
effective treatment regime is found. It is unlikely, in the
case presented, that prolonged surveillance would have
altered the life expectancy or mortality associated with
metastatic melanoma.
Recurrent metastatic malignant melanoma is a devastat-
ing disease, with a dismal prognosis. Further work is
required to determine a more effective treatment option.
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